Our approach is to show the clinical proof of concept for our unique drug delivery technology in one indication and to seek for a major partner within the biopharmaceutical industry.
First Indication: Eosinophilic Esophagitis
The lead indication is eosinophilic esophagitis (EoE), a rare inflammatory disease of the esophagus, with no worldwide approved treatment option at this stage. The symptoms of EoE include swallowing disorders, food impaction, vomiting, and heartburn. The only treatment options for the condition are extremely strict diets, off-label treatment with steroids or off-label proton pump inhibitors, or an orodispersible budesonide tablet available only in limited territories.
These treatment options remain suboptimal for the vast majority of affected patients.
EsoCap’s lead product will ensure a long-lasting topical delivery of mometasone, a well-established and highly potent locally acting steroid. It has the potential to establish a new standard of care and majorly improve the lives of affected people.
EsoCap is currently conducting the ACESO Phase II clinical study in EoE. The ACESO trial is a randomised, placebo-controlled, double-blind study evaluating the efficacy, tolerability and safety of the EsoCap product, ESO‑101, in adult patients with active eosinophilic esophagitis. The study is presently ongoing in 4 countries, Germany, the Netherlands, Spain and Switzerland.
The ACESO data will represent a major value inflection point and enable EsoCap to enter into a commercial transaction with a biopharmaceutical company.